肿瘤细胞减灭术加腹腔热灌注化疗治疗卵巢癌的术后不良事件分析  

Cross-sectional study of adverse events after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in patients with advanced or recurrent ovarian cancer

作　　者：桑秀波 李晓玉 龚萍[1] 李艳[1] 白文佩[1] 李雁 SANG Xiubo;LI Xiaoyu;GONG Ping;LI Yan;BAI Wenpei;LI Yan(Department of Obstetrics and Gynecology, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China)

机构地区：[1]首都医科大学附属北京世纪坛医院妇产科,北京100038 [2]首都医科大学附属北京世纪坛医院中心实验室,100038 [3]首都医科大学附属北京世纪坛医院腹膜肿瘤外科,100038

出　　处：《临床肿瘤学杂志》2022年第2期148-152,共5页Chinese Clinical Oncology

基　　金：北京市医院管理中心“登峰”计划专项经费资助项目(DFL20190701)。

摘　　要：目的探讨晚期卵巢癌及复发性卵巢癌患者经肿瘤细胞减灭术(CRS)和腹腔热灌注化疗(HIPEC)治疗后围手术期的不良事件情况。方法回顾性分析2015年4月至2019年7月收治的95例经CRS+HIPEC治疗的晚期卵巢癌或复发性卵巢癌患者的临床病理资料。结果原发性卵巢癌患者44例,复发性卵巢癌患者51例,死亡率和3~4级不良事件发生率分别为2.11%和29.5%。Logistic多因素分析显示直肠切除手术(OR=3.70,95%CI:1.29~10.59,P<0.05)是影响患者CRS+HIPEC术后严重不良事件的危险因素,而原发性卵巢癌、病理组织学类型和淋巴结转移非危险因素。结论CRS+HIPEC术后患者严重不良事件发生率低,围手术期安全性可接受。Objective To investigate the perioperative adverse events in patients with advanced or recurrent ovarian cancer treated with Cytoreductive surgery(CRS)and hyperthermic intraperitoneal chemotherapy(HIPEC).Methods Clinical and pathological data of 95 patients with advanced or recurrent ovarian cancer treated with CRS+HIPEC from April 2015 to July 2019 were retrospectively analyzed.Results There were 44 cases of primary ovarian cancer and 51 cases of recurrent ovarian cancer.The mortality rate and grade 3-4 adverse events rate were 2.11%and 29.5%,respectively.Logistic multivariate analysis showed rectal resection(OR=3.70,95%CI:1.29-10.59,P<0.05)was a risk factor for postoperative serious adverse events,while primary ovarian cancer,pathological tissue type of ovarian cancer and lymph node metastasis were not risk factors.Conclusion The incidence of serious adverse events in patients after CRS+HIPEC is low and the perioperative safety is acceptable.

关 键 词：卵巢癌 肿瘤细胞减灭术 腹腔热灌注化疗 不良反应 

分 类 号：R737.31[医药卫生—肿瘤]